ArticleJournal of neuro-oncology2012
Stereotactic radiosurgery for patients with recurrent intracranial ependymomas.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Radiosurgery for central nervous system ependymomas: a systematic review and meta-analysis.Journal of neuro-oncology · 2025Pooled it
- Pediatric cranial stereotactic radiosurgery: Meta-analysis and international stereotactic radiosurgery society practice guidelines.Neuro-oncology · 2025Guideline
- Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.Neuro-oncology · 2016Trial
- Stereotactic radiosurgery for the treatment of a distant recurrence of ependymoma on the optic nerve: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.Neuro-oncology · 2022Article
- Image-Guided Robotic Radiosurgery for the Management of Spinal Ependymomas.Frontiers in oncology · 2021Article
- Article
- Paediatric proton therapy.The British journal of radiology · 2020Review
- Re-irradiation of Recurrent Pineal Germ Cell Tumors with Radiosurgery: Report of Two Cases and Review of Literature.Cureus · 2016Review
- Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy.Japanese journal of radiology · 2016Article
- Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey.SpringerPlus · 2016Article
- Advances in Management of Pediatric Ependymomas.Current oncology reports · 2015Review
- The biology of radiosurgery and its clinical applications for brain tumors.Neuro-oncology · 2015Review
- Single-fraction stereotactic radiosurgery of meningeal hemangiopericytomas.Journal of neuro-oncology · 2014Article
- Fractionated stereotactic radiosurgery for recurrent ependymoma in children.Journal of neuro-oncology · 2014Article
- Multidisciplinary management of pediatric intracranial ependymoma.CNS oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study is to define the tumor control rate and complications associated with stereotactic radiosurgery (SRS) for patients with recurrent intracranial ependymoma. Retrospective review of 26 patients (49 tumors) having SRS between 1990 and 2008. Twenty-five patients (96 %) had undergone one or more craniotomies; one patient underwent SRS for a metastatic tumor after resection of a spinal ependymoma. Nineteen patients (73 %) had received cranial external beam radiotherapy (median dose, 54 Gy). Eight patients (31 %) were less than 18 years old. The median target volume was 2.2 cm(3) (range, 0.3-66.6); the median tumor margin dose was 18 Gy (range, 12-24). The median follow-up after SRS was 3.1 years (range, 3 months-13.1 years). The median overall survival after SRS was 5.5 years. The 1-year and 3-year survival rates were 96 and 69 %, respectively. Local tumor control (LC) was achieved in 33 of 49 lesions (67 %) with a median time to progression of 14.7 months (range, 2.9 months-11.2 years). The 1-year and 3-year progression-free survival rates were 80 and 66 %, respectively. The 1-year and 3-year LC rate was 85 and 72 %, respectively. On univariate analysis, higher tumor grade was associated with worse OS (grade 3-4, 27 % vs grade 2, 82 %, p = 0.04). Seven patients (27 %) had distant tumor progression and two patients (8 %) had symptomatic radiation necrosis after SRS. SRS for recurrent intracranial ependymoma provided good LC and may improve survival for patients with limited recurrent disease after prior treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.